Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN)) is a federal award for Aspr/Orm-Sns held by Biocryst Pharmaceuticals, Inc. Estimated value $69.4M ($13.9M obligated). Current period of performance ends Sep 29, 2025 (potential Sep 29, 2029). Last award drew 1 bidder. Place of performance: DURHAM NC. Related solicitation 75A50324Q00006.
PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN))
Recompete timing
PublicCurrent PoP ended Sep 29, 2025 (326 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50324F80012?
75A50324F80012 (Peramivir (rapivab 200mg 20ml (10mg ML) is a Aspr/Orm-Sns award with a potential value of $69.4M, currently held by Biocryst Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50324F80012?
Aspr/Orm-Sns awarded 75A50324F80012 to Biocryst Pharmaceuticals, Inc (potential $69.4M).
Who is the incumbent on 75A50324F80012?
Biocryst Pharmaceuticals, Inc is the incumbent. The current period of performance ends Sep 29, 2025.
When does Biocryst Pharmaceuticals, Inc’s 75A50324F80012 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 29, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.